SREBF1 and fatty liver disease: In conclusion, MV ameliorates HFD-induced hepatic steatosis through AMPK activation which regulates SREBP-1, PPAR-γ, and PPAR-α and thus improves the imbalance between lipid acquisition and lipid removal (Figure 5), providing us with a potential lead compound for developing new drug.